Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis

被引:82
作者
Buettner, Catherine [1 ,2 ]
Rippberger, Matthew J. [1 ]
Smith, Julie K. [3 ]
Leveille, Suzanne G. [1 ,2 ,4 ]
Davis, Roger B. [1 ,2 ,5 ]
Mittleman, Murray A. [2 ,6 ,7 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA
[4] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[7] Beth Israel Deaconess Med Ctr, Cardiovasc Epidemiol Res Unit, Boston, MA 02215 USA
关键词
Arthritis; Hydroxymethylglutaryl-CoA reductase inhibitors; Musculoskeletal diseases; Statins; ADVERSE EVENTS; METAANALYSIS; THERAPY; PREVALENCE; SYMPTOMS; OUTCOMES; TRIALS; IMPACT; RISKS;
D O I
10.1016/j.amjmed.2011.08.007
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND: Musculoskeletal symptoms are common adverse effects of statins, yet little is known about the prevalence of musculoskeletal pain and statin use in the general population. METHODS: We conducted a cross-sectional study of the National Health and Nutrition Examination Survey 1999-2004. We estimated the prevalence of self-reported musculoskeletal pain according to statin use and calculated prevalence ratio estimates of musculoskeletal pain obtained from adjusted multiple logistic regression modeling. RESULTS: Among 5170 participants without arthritis, the unadjusted prevalence of musculoskeletal pain was significantly higher for statin users reporting pain in any region (23% among statin users, 95% confidence interval [CI], 19-27, compared with 18% among those not using statins, 95% CI, 17-20; P = .02) and in the lower extremities (12% among statin users, 95% CI, 8-16, compared with 8% among those not using statins, 95% CI, 7-9; P = .02). Conversely, among 3058 participants with arthritis, statin use was not associated with higher musculoskeletal pain in any region. After controlling for confounders, among those without arthritis, statin use was associated with a significantly higher prevalence of musculoskeletal pain in any region, the lower back, and the lower extremities (adjusted prevalence ratios: 1.33 [CI, 1.06-1.67]; 1.47 [CI, 1.02-2.13]; 1.59 [CI, 1.12-2.22], respectively). Among participants with arthritis, no association was observed between musculoskeletal pain and statin use on adjusted analyses. CONCLUSION: In this population-based study, statin use was associated with a higher prevalence of musculoskeletal pain, particularly in the lower extremities, among individuals without arthritis. Evidence that statin use was associated with musculoskeletal pain among those with arthritis was lacking. (C) 2012 Elsevier Inc. All rights reserved. The American Journal of Medicine (2012) 125, 176-182
引用
收藏
页码:176 / 182
页数:7
相关论文
共 24 条
[1]
[Anonymous], FDA DRUG SAF COMM ON
[2]
Estimating Model-Adjusted Risks, Risk Differences, and Risk Ratios From Complex Survey Data [J].
Bieler, Gayle S. ;
Brown, G. Gordon ;
Williams, Rick L. ;
Brogan, Donna J. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 171 (05) :618-623
[3]
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study [J].
Bruckert, E ;
Hayem, G ;
Dejager, S ;
Yau, C ;
Bégaud, B .
CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) :403-414
[4]
Prevalence of musculoskeletal pain and statin use [J].
Buettner, Catherine ;
Davis, Roger B. ;
Leveille, Suzanne G. ;
Mittleman, Murray A. ;
Mukamal, Kenneth J. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (08) :1182-1186
[5]
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy [J].
Cannon, Christopher P. ;
Steinberg, Benjamin A. ;
Murphy, Sabina A. ;
Mega, Jessica L. ;
Braunwald, Eugene .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (03) :438-445
[6]
Centers for Disease Control and Prevention, About the National Health and Nutrition Examination Survey
[7]
Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes [J].
Cheung, BMY ;
Lauder, IJ ;
Lau, CP ;
Kumana, CR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (05) :640-651
[8]
FDA Public Health Advisory for Crestor (rosuvastatin), POSTM DRUG SAF INF P
[9]
Effective strategies for long-term statin use [J].
Fonarow, GC ;
Watson, KE .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (1A) :27I-34I
[10]
A comprehensive description of muscle symptoms associated with lipid-lowering drugs [J].
Franc, S ;
Dejager, S ;
Bruckert, E ;
Chauvenet, M ;
Giral, P ;
Turpin, E .
CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (5-6) :459-465